Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Patent
1998-03-16
2000-11-14
Qazi, Sabiha N.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
514169, 514177, 514178, A61K 3156
Patent
active
06147066&
DESCRIPTION:
BRIEF SUMMARY
Use of compounds having an antimineralocorticoid activity for the preparation of medicaments intended for the prevention or treatment of symptoms linked to drug dependence or to the spontaneous or induced withdrawal syndrome, caused by narcotics and the compositions containing them.
The products having an antimineralocorticoid activity are known as being able to be used as medicaments. They are, in particular, antagonists of aldosterone and they increase salt and water diuresis with conservation of organic potassium; moreover they have, for some, the advantage of being devoid of hormonal side-effects, in particular anti-androgen and anti-estrogen effects. They can therefore be used to combat, in particular, arterial hypertension and cardiac insufficiencies.
There are two major types of glucocorticoid receptor at the level of the central nervous system, the type I receptor and the type II receptor (R. Ahima et al. J. Comp. Neurol. 313 (1991) 522-528; Neuroscience 39 (1990) 579-604).
The type I receptor, at the level of the brain, is identical to the standard mineralocorticoid receptor found at the level of the kidney, and it has a high affinity and a low bonding capacity for the endogenous glucocorticoids. In others terms, an antimineralocorticoid behaves at the level the central nervous system as a type I antiglucocorticoid.
The Applicant has demonstrated the new and unexpected use of these products, mentioned above.
It has previously been shown that the glucocorticoids (dexamethasone type) antagonize the analgesic activity of morphine while an antagonist of the glucocorticoids, of 17.beta.- hydroxy 11.beta.-(4-dimethylaminophenyl) 17.alpha.-(prop-1-ynyl) estra 4,9-diene-3-one type, or a suprarenalectomy, potentializes this activity (Capasso et al. Life Science 51 139 (1992), Ratka et al. Neuroendocrinology 49 439 (1988) Pieretti et al. Gen. Pharmacol. 22 929 (1991)).
However, to the knowledge of the Applicant, nobody has demonstrated the activity of an antimineralocorticoid vis-a-vis the undesirable effects of opiates and in particular of the induction of a physical or psychological dependent state and the withdrawal syndrome associated with this state. These dependence and withdrawal phenomena involve complex central mechanisms, multiple and different from those which are observed in the analgesic activity of opiates.
On the other hand, recent data has been reported on the important role that the endogenous glucocorticoids could play in the symptoms of narcotic withdrawal, as well as in the dependence phenomena induced by opiates or cocaine. Thus, hypercortisolism has been observed in man over the course of clinical trials, during withdrawal spontaneous or induced by naloxone consecutive with taking heroin or morphine (Cami et al. Br. J. Addict 87 1145 (1992), Higgins et al. Drug Alcohol Depend. 30 13 (1992). Other elements reported in animals show an activation of the hypothalamo-surrenal axis by cocaine (Borowsky and Kuhn, J. Pharmacol. Exp. Ther. (1991) 256, 204) administered in an acute or repeated treatment with an increase in plasmatic levels of corticosterone and ACTH (Moldow and Fischman, Peptides 8 819 (1987), Yang et al. Pharmacol. Biochem Behau. 41 643 (1992), Saphier et al. Neuroendocrinology 57 54 (1993)) consecutive with a mediation of monoaminergic origin (dopamine for example). For example the involvement of the dopaminergic system appears confirmed by the fact that haloperidol and metoclopramide (dopaminergic antagonists) oppose respectively the increase in corticosterone levels induced by cocaine and the phenomenon of morphinic withdrawal (Ramaswamy and Bapna, Life Science 40 807 (1987)).
This data appears to show that the endogenous glucocorticoids could intervene in the phenomena of withdrawal and dependence, in the same way as dopaminergic mechanisms but at a stage further upstream than the latter.
These different elements have justified the study of antagonists of mineralocorticoids in particular vis-a-vis the phenomena of physical and psychological dependence or morphinic withdrawa
REFERENCES:
patent: 5413993 (1995-05-01), Soma et al.
Farmakol, Toksikol, vol. 41, No. 5, 1978 pp. 541-533.
Eur. J. Pharmacol. vol. 56, No. 3, 1979 pp. 197-205.
J. Pharmacol. Exp. Ther, vol. 236, No. 1, 1986 pp. 157-165.
Fed. Proc. vol. 40, No. 5, 1981 pp. 1502-1507.
Eur. J. Pharmacol. vol. 263, No. 1-2, 1994 pp. 149-156.
Wei , E. (CA 79:49219 abstract of Brit. J. Pharmacol. (1973), 47(4), 693-9).
El'tsova et al (CA 89:191592 abstract of Farmkol. Tokshikol. (Moscow) (1978), 41(5), 541-4).
Budziszewska et al. (CA 125:49548 abstract of Eur. Neuropsychopharmacol. (1996), 6(2), 135-140).
Goodman and Gilman (The Pharmaceutical Basis of Therapeutics, 7th edition, Macmillan publishing Company, New York, 1985, pp. 568-571).
Goeders Nick
Petit Francis
Philibert Daniel
Qazi Sabiha N.
Roussel Hoechst Marion
LandOfFree
Use of antimineralocorticoid compounds against drug withdrawal s does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of antimineralocorticoid compounds against drug withdrawal s, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of antimineralocorticoid compounds against drug withdrawal s will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2065582